INTRODUCTION {#sec0005}
============

Dementia is a devastating disease affecting millions of people worldwide. While advances over the past decades have unraveled several pathological mechanisms underlying dementia, chronological age remains the most important predictor for dementia onset \[[@ref001]\]. There is, therefore, a wide interest in biomarkers that capture the burden of detrimental factors as these accumulate with the passage of time, i.e., increasing age. Such markers, that are preferably easily quantified, may aid in disentangling the etiology of dementia or ultimately serve as predictive markers. Against this background, telomere length has received considerable attention \[[@ref002]\].

Telomeres are repetitive base pair sequences at the end of chromosomes and facilitate complete chromosome replication \[[@ref003]\]. Since the replication machinery is unable to copy the ends of DNA, telomeres will shorten with each cell division. A change in telomere length resulting in shortened telomeres induces a DNA damage response that leads to a growth arrest during which cells attempt to repair the damage and if DNA damage is irreparable, replicative senescence or cell death is triggered \[[@ref004]\]. Very short telomeres have relatively low cancer risk (due to cell senescence blocking cell division), but could be associated with increased DNA damage \[[@ref005]\]. Given the tight link with cell death, short telomere length has been linked to poorer survival \[[@ref006]\] and other age-related diseases, including dementia as has been shown in a recent meta-analysis \[[@ref008]\]. Conversely, there is evidence that over-elongated telomeres represent pathological cell function with decreased DNA repair and increased cancer risk \[[@ref009]\], which has also been shown in human embryonic stem cells \[[@ref010]\], while "normally" long telomeres are protective, including against DNA damage. With respect to Alzheimer's disease, there is also evidence suggesting an increased risk of mild cognitive impairment related to both short and long telomeres \[[@ref011]\]. Additionally, hippocampal cells of Alzheimer's disease brains are shown to have longer telomeres compared to control samples \[[@ref012]\]. It is, thus, conceivable that not only shorter but also longer telomere length may be detrimental for dementia risk. However, the temporal relation between longer telomere length and dementia has so far not been investigated. Therefore, the aim of this study is to investigate the association between blood cell telomere length and risk of Alzheimer's disease and to explore non-linearity within this association.

METHODS {#sec0010}
=======

Design and study population {#sec0015}
---------------------------

This study was embedded within the Rotterdam Study, a prospective population-based cohort study among middle-aged and elderly individuals in the Netherlands. Three cohorts were established in 1990, 2000, and 2006, respectively. From each cohort, participants were invited every 4--5 years to undergo follow-up examinations. We refer the reader to the Rotterdam Study methods paper for further information \[[@ref013]\]. For this study, a total of 2,140 participants were randomly selected from the first (1990--2004, N = 7983) and third cohorts (2006--2008, N = 3932) for telomere length measurement. From these participants, 1,961 were dementia-free at baseline visit and had complete telomere length data available at baseline ([Fig. 1](#jad-73-jad190759-g001){ref-type="fig"}).

![Flowchart of study population.](jad-73-jad190759-g001){#jad-73-jad190759-g001}

The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus MC and by the Ministry of Health, Welfare and Sport of the Netherlands, implementing the Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study). All participants provided written informed consent to participate in the study and to obtain information from their treating physicians.

Assessment of telomere length {#sec0020}
-----------------------------

Blood for all samples was collected in EDTA tubes and stored at --20°C until DNA isolation. DNA isolation was done with a method based on salting out, with different lysis buffers for the different cohorts. The OD260/280 and OD260/230 for both isolation methods did not differ significantly between the two cohorts. The average OD260/280 ratio was 1.90 with a standard deviation of 0.10 and the average OD260/230 ratio was 1.61 with a standard deviation of 0.46 in a random sample of 168. Telomere length was measured using a qPCR assay based on the method described by Cawthon \[[@ref014]\] with minor modifications. The SDS software of the 7900HT qPCR machine is not able to analyze the qPCR data produced at two different temperature points. Therefore, we chose the singleplex assay for this study. For each sample, the telomere and 36B4 assay were run in separate wells but in the same 384 wells PCR plate. Each reaction contained 5 ng DNA, 1*μ*M of each of the telomere primers (tel1b-forward: G.2ptG.2ptT.2ptT.2ptT.2ptG.2ptT.2ptT.2ptT.2ptG.2ptG.2ptG.2ptT.2ptT.2ptT.2ptGGGTTTGGGTTTGGGTTTGGGTT, tel2b-reverse: GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT) or 250 nM of the 34B4 primers (36B4u-forward: CAGCAAGTGGGAAGGTGTAATCC, 36B4d-reverse: CCCATTCTATCATCAACGGGTACAA) and 1× Quantifast SYBR green PCR Mastermix (Qiagen). The reactions for both assays were performed in duplicate for each sample in a 7900HT machine (Applied Biosystems). Ct values and PCR efficiencies were calculated per plate using the MINER algorithm \[[@ref015]\]. Duplicate Ct values that had a coefficient of variance (CV) of more than 1% were excluded from further analysis. Using the average Ct value per sample and the average PCR efficiency per plate the samples were quantified using the formula *Q* = 1/(1 + PCR eff)^∧^Ct. The relative telomere length was calculated by dividing the Q of the telomere assay by the Q of the 34B4 assay. To validate the assay, 96 random samples were run twice and the CV of that experiment was 4.5%. Telomere length was measured in 37 batches.

Ascertainment of incident dementia {#sec0025}
----------------------------------

Baseline and follow-up ascertainment methods for dementia have previously been described in detail \[[@ref016]\]. In brief, participants were screened for dementia at baseline and subsequent center visits. In addition, the entire cohort was continuously under surveillance for dementia through electronic linkage of the study database with medical records. A consensus panel led by a consultant neurologist established the final diagnosis according to standard criteria for dementia (DSM-III-R) and Alzheimer's disease (NINCDS--ADRDA). Within this period, participants were censored at date of dementia diagnosis, death, loss to follow-up, or 1 January 2016, whichever came first.

APOE genotyping {#sec0030}
---------------

*APOE* genotype was determined using polymerase chain reaction on coded DNA samples in the baseline cohort \[[@ref017]\] and with a bi-allelic Tacqman assay (rs7412 and rs429358) in the extensions of the Rotterdam Study \[[@ref013]\]. *APOE* *ɛ*4 carrier status was defined carriers versus non-carriers of the *ɛ*4 allele.

Other covariates {#sec0035}
----------------

Potential confounding factors were chosen on the basis of previous literature \[[@ref016]\]. All covariates were measured at baseline. Educational attainment was categorized as low (primary education or lower vocational education), intermediate (secondary education or intermediate vocational education), and high educational level (higher vocational education or university). Smoking habits were categorized as current, former and never smoking. Body mass index was calculated as weight in kilograms per height in meters squared. Blood pressure was measured twice at the right brachial artery with the participant in sitting position, out of which the mean was used. Hypertension was defined as a resting blood pressure exceeding 140/90 mmHg or the use of blood pressure lowering medication. Hypercholesterolemia was defined as a total cholesterol of ≥6.2 mmol/L or the use of serum lipid-reducing agents. White blood cell counts were assessed with a Coulter AcT diff2 Hematology Analyzer at the research center in Ommoord. On 14 February 2005, a new device of the same brand and type was installed. Prevalent stroke was assessed at baseline during interview and we verified these data with medical records. After study entry, we continuously monitored participants after enrollment for incident stroke through linkage of the study database with files from general practitioners. Files of nursing home physicians and files from general practitioners of participants who moved out of the district were also checked. We obtained additional information from hospital records. When potential strokes were found, they were reviewed by research physicians and verified by an experienced neurologist.

Statistical analysis {#sec0040}
--------------------

Missing covariate data (maximum 2.2%) were imputed using 5-fold multiple imputation based on determinant, outcome, and included covariates. In all models, we adjusted for age continuously, sex and center visit since data was randomly selected from 4 center visits from 2 subcohorts. We additionally adjusted for educational attainment, *APOE* *ɛ*4 carrier status, smoking, body mass index, hypertension, hypercholesterolemia, and white blood cell count in a second model, all at time of blood draw. We first explored linearity of telomere length with Alzheimer's disease and dementia risk by entering T/S ratio as restricted cubic spline with 3 knots in Cox regression models. In order to further quantify potential non-linearity, T/S ratio was subsequently divided into tertiles, defined as T/S ratio of 0.31--0.87, 0.87--1.02, and 1.02--1.79, respectively. To provide a parsimonious description of the telomere-dementia relationship and facilitate communication of the results, we assessed the association between telomere length in tertiles, comparing lowest and highest tertiles that represent the shortest and longest telomere lengths, respectively, to the middle tertile, with risk of Alzheimer's disease and dementia. We repeated the analysis for Alzheimer's disease, by adjusting not only for age at blood draw, but also for age at dementia diagnosis or date of last follow-up as an attempt to assess survival bias. We further verified that age was robustly controlled for by comparing results across models using five different ways of age-adjustment. These included no adjustment for age, entering age and age^2^ in the model, entering age as cubic splines, repeating the analyses with age rather than follow-up time as the time scale and finally regressing the effect of age out of T/S ratio before creating T/S ratio tertiles. We performed an additional adjustment for plate number to rule out batch effects. The proportional hazards assumption was assessed using Schoenfeld residuals. We next repeated the analyses for Alzheimer's disease, but excluding all participants with prior clinical stroke at baseline and censoring for incident clinical stroke during follow-up using Cox models.

We also assessed interaction by age, sex, education, or *APOE* *ɛ*4 carrier status by stratification and testing for multiplicative interaction by including the product of the interacting factor and T/S ratio continuously as a restricted cubic spline (4 knots) to take into account the non-linear relationship between T/S ratio and Alzheimer's disease. We stratified for age by 3 groups, namely 45--65 years, 65--85 years, and 85--105 years.

All analyses were performed using RStudio version 0.99.903 (R version 3.4.3 \[[@ref019]\], RStudio, Inc., Boston, MA). We used the following R packages for our analyses: mice, survival, rms, and scales.

RESULTS {#sec0045}
=======

Baseline characteristics of the study population are presented in [Table 1](#jad-73-jad190759-t001){ref-type="table"}. The mean age of the participants was 71.4±9.3 years with 57.1% women. During a median follow-up of 7.3 (interquartile range 4.9--11.7) years (26,025 person-years), 305 individuals were diagnosed with dementia of whom 237 were Alzheimer's disease.

###### 

Baseline characteristics of the dementia-free study population

  Characteristics                                       Dementia-free cohort (N = 1961)
  ---------------------------------------------------- ---------------------------------
  Women                                                          1120 (57.1%)
  Age, y                                                           71.4±9.3
  Cohort                                               
    First                                                        1543 (78.7%)
    Third                                                         418 (21.3%)
  Education                                            
    Primary education                                             366 (18.9%)
    Lower/intermediate general education                          806 (41.5%)
    Intermediate vocational education                             535 (27.6%)
    Higher vocational education                                   233 (12.0%)
  Apolipoprotein E *ɛ*4 carriership                    
    Non-carrier (*ɛ*2/*ɛ*2, *ɛ*2/*ɛ*3, or *ɛ*3/*ɛ*3)             1411 (72.0%)
    Carrier (*ɛ*4/*ɛ*4, *ɛ*3/*ɛ*4, or *ɛ*2/*ɛ*4)                  550 (28.0%)
  Smoking                                              
    Current                                                       405 (21.1%)
    Former                                                        921 (48.0%)
    Never                                                         592 (30.9%)
  Body mass index, kg/m^2^                                         27.2±4.1
  Hypertension                                                    700 (36.5%)
  Hypercholesterolemia                                            949 (48.8%)
  White blood cell count                                            6.9±2.3
  Telomere length, T/S ratio                                       0.95±0.18

N, number of participants included in study. Data presented as mean (standard deviation) for continuous variables and number (percentages) for categorical variables. T/S ratio is relative telomere to single copy gene ratio. Data represent original data without imputed values. Number of missing values are 43 (2.2%) for smoking, 21 (1.1%) for education, 27 (1.4%) for hypertension, 17 (0.9%) for hypercholesterolemia, 29 (1.5%) for body mass index, and 157 (8.0%) for white blood cell count. Data for apolipoprotein E *ɛ*4 carriership was complete.

There was evidence of non-linearity in the association between telomere length and Alzheimer's disease ([Supplementary Figure 1](#S1){ref-type="supplementary-material"}). Compared to the middle tertile of telomere length, we found an adjusted hazard ratio (aHR) of 1.59; 95% confidence interval (CI), 1.13--2.23 for lowest tertile of telomere length and 1.47; 95% CI, 1.03--2.10 for highest tertile of telomere length for Alzheimer's disease, with similar but lower estimates for dementia ([Table 2](#jad-73-jad190759-t002){ref-type="table"}). When additionally adjusting for age at dementia diagnosis or date of last follow-up, we found an aHR of 1.52; 95% CI, 1.07--2.18 for lowest tertile of telomere length and 1.75; 95% CI, 1.21--2.54 for highest tertile of telomere length for Alzheimer's disease, compared to the middle tertile. Other approaches of age-adjustment yielded similar results ([Table 3](#jad-73-jad190759-t003){ref-type="table"}). There were no batch effects. The proportional hazards assumption was met for all models. Results were slightly attenuated but remained U-shaped after excluding participants with prior clinical stroke at baseline and censoring for incident clinical stroke: compared to middle tertile aHR: 1.44, 1.02--2.05 for lowest tertile of telomere length and aHR 1.30, 95% CI 0.90--1.89 for highest tertile of telomere length.

###### 

Telomere length and the risk of Alzheimer's disease and all-cause dementia

                                        n/N     Alzheimer's disease         n/N          All-Cause dementia                     
  ---------------------------------- --------- --------------------- ------------------ -------------------- ------------------ ------------------
  **Telomere length**                                                                                                           
  Tertile 1 (T/S ratio 0.31--0.87)    106/654    1.54, 1.10--2.15     1.59, 1.13--2.23        129/654         1.25, 0.94--1.66   1.27, 0.96--1.70
  Tertile 2 (T/S ratio 0.87--1.02)    54/654       1 (reference)       1 (reference)           80/654          1 (reference)      1 (reference)
  Tertile 3 (T/S ratio 1.02--1.79)    77/653     1.41, 0.99--2.00     1.47, 1.03--2.10         96/653         1.19, 0.88--1.60   1.25, 0.92--1.69

n, number of cases; N, number of persons at risk; HR, hazard ratio; CI, confidence interval; T/S ratio, relative telomere to single copy gene ratio. Cox regression model I: Adjusted for age, sex, and visit. Cox regression model II: Adjusted for age, sex, visit, education, *APOE* *ɛ*4 carrier status, smoking, body mass index, hypertension, hypercholesterolemia, and white blood cell count.

###### 

Association between telomere length and Alzheimer's disease using different modes of age adjustment

  Adjustment              Alzheimer's disease                                                                              
  ---------------------- --------------------- ------------------ ------------------ ------------------ ------------------ ------------------
  **Telomere length**                                                                                                      
  Tertile 1 (shortest)          106/654         2.08, 1.49--2.91   1.64, 1.17--2.30   1.64, 1.17--2.30   1.63, 1.16--2.29   1.33, 0.96--1.86
  Tertile 2 (middle)            54/654           1 (reference)      1 (reference)      1 (reference)      1 (reference)      1 (reference)
  Tertile 3 (longest)           77/653          1.25, 0.88--1.77   1.45, 1.01--2.06   1.45, 1.02--2.06   1.44, 1.01--2.06   1.22, 0.87--1.69

n, number of cases; N, number of persons at risk; HR, hazard ratio; CI, confidence interval; T/S ratio, relative telomere to single copy gene ratio. ^†^Cubic splines with 3 knots, similar results for higher degree polynomials. Models adjusted for age, sex, visit, education, *APOE* *ɛ*4 carrier status, smoking, body mass index, hypertension, hypercholesterolemia, and white blood cell count. ^\*^Regressing the effect of age out of T/S ratio before creating T/S ratio tertiles; no additional adjustment for age in the model; similar results for additionally regressing out the effect of sex.

In the stratified analyses, the association between shorter and longer telomeres and Alzheimer's disease was stronger in *APOE* *ɛ*4 carriers compared to non-carriers ([Fig. 2](#jad-73-jad190759-g002){ref-type="fig"}) with the multiplicative interaction term yielding *p* = 0.087. Stratification for age, sex, and education did not provide different risk estimates (*p-*values for interaction: *p* = 0.554, *p* = 0.600, and *p* = 0.123, respectively).

![A visual representation of telomere length and the risk of Alzheimer's disease stratified by *APOE* *ɛ*4 carriership with restricted cubic splines in Cox model II, adjusted for age, sex, study visit, education, *APOE* *ɛ*4 carrier status, smoking, body mass index, hypertension, hypercholesterolemia and white blood cell count. Number of Alzheimer's disease cases in *APOE* *ɛ*4 carrier group: 102 with 550 persons at risk; number of cases in the *APOE* *ɛ*4 non-carrier group: 135 with 1411 persons at risk.](jad-73-jad190759-g002){#jad-73-jad190759-g002}

DISCUSSION {#sec0050}
==========

In this study, shorter as well as longer telomere length were significantly associated with increased risk of dementia, specifically Alzheimer's disease.

Thus far, focus in the dementia field has been on shorter telomere length with studies finding observationally as well as genetically associations between shorter telomere length and increased risk of Alzheimer's disease \[[@ref020]\]. Moreover, a recent meta-analysis which included 13 primary studies demonstrated significantly shorter telomere length in 860 Alzheimer's disease patients compared to 2,022 controls \[[@ref008]\]. Interestingly, we found that in addition to shorter telomere length also longer telomere length was associated with an increased dementia risk. This finding is in line with previous studies \[[@ref024]\], particularly the study by Roberts and others \[[@ref011]\] showing that short and long telomeres increase risk of amnestic mild cognitive impairment. Yet, we emphasize that further replication is necessary to confirm the robustness of our findings with dementia.

An explanation for our observations with longer telomere length might be survival bias, where presumably participants with the longest telomere length live long enough to develop dementia. This is, however, less likely since associations remained after additional adjustment for age at dementia diagnosis or end of follow-up. Alternatively, it is plausible that a disturbed equilibrium of telomere length toward either direction is harmful. Indeed, over-elongated telomeres become fragile and accumulate DNA damage, as has been shown by an experimental study in human embryonic stem cells, and very tight control of telomere length homeostasis is regulated by not only telomerase-dependent elongation, but also by telomere trimming events \[[@ref010]\]. Another study has shown that telomerase RNA component (TERC) knockout mice with Alzheimer's disease, which present with telomere shortening, slows down the progression of Aβ pathology, showing a more protective effect of short telomere length \[[@ref026]\], thereby supporting a detrimental effect of longer telomere length. The potential biological link between over-elongated telomeres and higher Alzheimer's disease risk remains to be further elucidated. In contrast with longer telomere length, more is known about the potential biological link between shorter telomeres and increased Alzheimer's disease risk. Neurons lacking telomerase reverse transcriptase (TERT) in knockout mice and thus have shorter telomeres, display an increased production of oxidative species and an increase in cellular oxidative damage in response to tau, demonstrating a harmful effect of shorter telomeres \[[@ref027]\]. Therefore, telomerase may play different roles in the tau and amyloid pathology via multiple mechanisms \[[@ref028]\]. In addition, microglial cellular senescence may also be an important mechanism in the development of Alzheimer's disease, which is suggested to be exacerbated by the presence of amyloid \[[@ref029]\]. Further studies are warranted to differentiate between a true biological association and survival bias. If a true biological association exists between longer telomere length and risk of dementia, telomerase therapies, which have been successful in mice \[[@ref031]\], would need further fine-tuning to prevent over-elongation of telomere length.

Interestingly, we found stronger effects for Alzheimer's disease compared to all-cause dementia. This might be reflective of the fact that Alzheimer's disease is a more homogeneous entity than all-cause dementia, which includes a plethora of etiologies.

Certain limitations must be taken into account. First, we measured telomere length in leukocytes in blood. This may not be representative of telomere length in the brain, in particular glial cells. However, a previous study has shown a direct correlation between telomeres measured from peripheral blood and cerebellum \[[@ref033]\], suggesting blood cell telomere length to be a valid measurement. Another limitation of measuring telomere length in leukocytes is that lymphocytes are the only peripheral blood cells expressing telomerase activity and therefore are able to maintain telomere length despite proliferation, while granulocytes lack the ability for further cell division \[[@ref034]\]. Therefore, it is possible that the older individuals without dementia have a greater proportion of lymphocytes (fewer granulocytes) \[[@ref035]\], and thus longer telomere length. Unfortunately, we were not able to adjust for the percentage of lymphocytes to overcome this issue, since this data was not available for all center visits. Another issue is that leukocytes divide peripherally in response to various stresses (e.g., infection) and the telomere length may therefore change unexpectedly. Also, research centers may vary in reliability in measuring leukocyte telomere length. Second, we measure mean telomere length, while cell senescence is suggested to be related to and modulated by the shortest telomere length per cell \[[@ref036]\]. Third, the external validity of the results may be limited due to the single center nature of this study. Finally, despite using different approaches yielding similar results, the effect of age may not have been taken into account entirely. Nevertheless, given the link of older age with shorter telomere length and older age with Alzheimer's disease, controlling for age would if anything strengthen the association between longer telomere length and risk of Alzheimer's disease.

In conclusion, shorter and longer telomere length are associated with an increased risk of Alzheimer's disease in a sample of elders in The Netherlands. Further studies are warranted to confirm our findings, in particular studies with imaging or fluid biomarkers available for dementia diagnosis, and to unravel any underlying biological pathway from possible methodological bias.

Supplementary Material
======================

###### Supplementary Figure

###### 

Click here for additional data file.
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